Page 5 - Dr Reddy's Laboratories Limited

Adani Green could replace Dr Reddy's in Sensex during December review

If added, Adani Green will be the first stock from the group in Sensex. After the inclusion of Adani Enterprises by September-end, Nifty will have two Adani group constituents

Dr Reddy's Q1 PAT soars 108% to Rs 1,188 cr; revenue rises 6%

Other operating income was at Rs 600 crore compared to Rs 50 crore in Q1FY22

Dr Reddy's Lab says its Andhra plant gets two observations from USFDA

Dr Reddy's Laboratories Ltd on Thursday said the US health regulator has issued Form 483 with two observations after inspecting its manufacturing facility located at Srikakulam in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The US Food and Drug Administration (USFDA) completed a pre-approval inspection at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh on Thursday, Dr Reddy's said in a regulatory filing. The inspection was conducted from June 30, 2022 to July 7, 2022. "We have been issued a Form 483 with two observations, which we will address within the stipulated timeline," the company added.

JB Chem gets board approval to acquire Dr Reddy's 4 brands for Rs 98 cr

JB Chemicals & Pharmaceuticals on Thursday said its board has approved a proposal to acquire four paediatric brands from Dr Reddy's Laboratories for about Rs 98 crore. The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing. The company has inked a pact with Dr Reddy's Laboratories to acquire four of its brands -- Z&D, Pedicloryl, Pecef and Ezinapi -- for the India market, it added. All four brands are focused on the paediatric segment in the country with a total covered market size of Rs 1,800 crore as per IQVIA data, JB Chemicals & Pharmaceuticals said. The combined sales of these brands stood at around Rs 33 crore for FY 2021-22, it added. The acquisition, which will be funded primarily through long-term debt, will be completed in the next few working days, the drug firm stated.

Dr Reddy's subsidiary inks pact with US-based Olema Pharmaceuticals

Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of a target

Torrent Pharma acquires four therapy segment brands from Dr Reddy's

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company

Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).

Dr Reddy's Lab to approach regulator for Sputnik Light as booster dose

Dr Reddy's Laboratories is hoping to go to a regulator for its single-dose Sputnik Light jab as booster dose for approvals by June-end or early July, a senior official said

75% of Nifty50 stocks trade below 200-DMA; look weak on the charts

Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so far in calendar year 2022 (CY22)

Stocks to Watch: Mahindra CIE, Dilip Buildcon, SIS, Butterfly Gandhimathi

Stocks like Sun Pharma, Dr.Reddy's and others having exposure to Europe are likel to be in focus as the Russia-Ukraine crisis deepens.

Dr Reddy's Laboratories inks exclusive sales pact with Novartis India

Dr Reddy's Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said

Dr Reddy's Laboratories to introduce Molnupiravir to treat Covid-19 shortly

The Hyderabad-based firm said it will introduce the drug under the brand name Molflu in India

Sensex, Nifty end flat; Star Health settles at issue price; PSBs shine

The broader markets outperformed, the BSE Midcap and Smallcap indices were up 0.3 per cent and 0.8 per cent, respectively

Covid: Dr Reddy's eyes Sputnik vaccine exports after domestic struggle

Now, Dr Reddy's is focusing on the single-dose Sputnik Light, as a booster shot or standalone, instead of the two-dose Sputnik V, a spokesperson said

BSE Healthcare index up 2%; Cipla, Alkem, Dr.Reddy's rally up to 8%

The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.

Without innovation Indian pharma cannot touch $130 bn by 2030: Industry

Sun Pharma says it eyes $1.5 bn from innovative products in 3-4 years

Fag-end buying in IT, banks lifts Sensex 831 pts at 60,138, Nifty at 17,930

The broader markets also logged strong gains, with the Midcap index up 1.8 per cent and the Smallcap index adding up 1.1 per cent

Dr Reddy's Laboratories working on enhancing Covid-19 portfolio

As for MSD's drug Molnupiravir, which is currently undergoing clinical trial in India, the company said it has already shared interim data with the drug regulator

Dr Reddys Labs gains 7% as profit grows 30% YoY in Q2, margins expand

Dr Reddy's global generic business grew 19 per cent YoY to Rs 4,743 crore driven by covid portfolio, new product launches and base business volume traction across key markets.

Dr Reddy's Lab receives USFDA approval to market Lenalidomide capsule

Dr Reddy's Laboratories on Tuesday said it has received approval from the US health regulator to market Lenalidomide capsules